Drug Combination Details
| General Information of the Combination (ID: C26286) | |||||
|---|---|---|---|---|---|
| Name | Vitamin E NP Info | + | Gefitinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Renal fibrosis
[ICD-11: MF54]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | NRK-49F | CVCL_2144 | Healthy | Rattus norvegicus | ||
| Experimental
Result(s) |
A combined treatment with low-dose gefitinib and vitamin E has synergistic effects that reduce TGF Beta1 induced fibroblast proliferation, cell-cycle arrest and the ERK phosphorylation pathway. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combined treatment with vitamin E and gefitinib has synergistic effects to inhibit TGF-Beta1-induced renal fibroblast proliferation. Mol Med Rep. 2016 Jun;13(6):5372-8. | |||
